Related Experiment Video

Updated: Jun 12, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Targeted treatment and new agents in follicular lymphoma

Bruce D Cheson1

  • 1Lombardi Comprehensive Cancer Center, Georgetown University Hospital, 3800 Reservoir Road N.W., Washington, DC 20007, USA. bdc4@georgetown.edu

International Journal of Hematology
|June 25, 2010
PubMed

Insights

Follicular lymphoma treatments are improving with new drugs and combinations. Research focuses on novel agents and understanding resistance to enhance patient survival for this incurable cancer.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Follicular lymphoma is an indolent, incurable hematologic malignancy.
  • Standard chemotherapy combinations have not improved outcomes for follicular lymphoma patients.
  • Monoclonal antibodies (MoAbs) like rituximab have shown efficacy in prolonging survival.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for follicular lymphoma.
  • To highlight the role of novel agents and combination therapies.
  • To emphasize the importance of understanding drug mechanisms and tumor biology.

Main Methods:

  • Review of current literature on follicular lymphoma treatment.
  • Analysis of novel therapeutic agents targeting cellular pathways and the tumor microenvironment.
  • Discussion of combination strategies and correlative studies.

Main Results:

  • New agents, including bendamustine, bortezomib, and lenalidomide, are being evaluated.
  • Targeted therapies inhibiting spleen tyrosine kinase, mTOR, PI3-kinase, and apoptosis show promise.
  • Combination strategies are essential for improving treatment efficacy.

Conclusions:

  • While follicular lymphoma remains incurable, novel therapies offer improved survival.
  • Rational development of combination strategies is key to advancing treatment.
  • Further research into drug mechanisms and tumor biology will enhance patient outcomes.

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...